On the other hand, the effect of CYP2W1 SNPs is currently unclear and, contrary to what has been described for duocarmycin analogs in colon cancer cells [23], CYP2W1*6 may have a different catalytic capacity for mitotane metabolism. Here, CYP2W1 is linked to malignant colon neoplasm.